Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ono, Univ. of Tokyo Sign Joint Research Agreement for Drug Discovery Target Identification
September 29, 2011
- MTPC to Start PIII Trial for Telaprevir in China Early 2012
September 29, 2011
- NBI Releases Latest PMS Results for Prazaxa
September 28, 2011
- Rivaroxaban Recommended for Approval in EU: Bayer
September 28, 2011
- Astellas Pharma Debuts on DJSI Asia Pacific Index
September 28, 2011
- Kowa, NanoCarrier Announce License Agreement for Epirubicin Micelle
September 28, 2011
- Dry Eye Treatment Mucosta Ophthalmic Suspension Approved: Otsuka
September 27, 2011
- Teva to Resolve Joint Venture with Kowa, Acquire 100% Stake in Teva-Kowa
September 27, 2011
- Japan’s First Oral MS Treatment Imusera/Gilenya Approved: MTPC/Novartis
September 27, 2011
- Prazaxa Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
September 27, 2011
- Breast Cancer Treatment Faslodex Approved: AZ
September 27, 2011
- BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end
September 27, 2011
- COPD Treatment NVA237 Filed in Europe by Novartis: Sosei
September 27, 2011
- Novartis Announces New PIII Data for Inhaled Therapy NVA237 at ERS Congress
September 27, 2011
- Daiichi Sankyo Unable to Ship 2.36 million Vials of Flu Vaccine Due to Virus Contamination
September 26, 2011
- OncoTherapy To Receive Milestone Payment following Submission of PI Clinical Trial Certificate
September 26, 2011
- Shanghai Genomics Receives New Drug Certificate for the Treatment of IPF in China
September 26, 2011
- Astellas: OAB Treatment Betanis Tablets
September 26, 2011
- Ono/Astellas: Once-Every-Four-Weeks Formulation of Recalbon, Bonoteo
September 26, 2011
- MTPC, Janssen Pharma Launch RA Treatment Simponi
September 26, 2011
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…